EMA Finalizes Key Guideline On Use Of Digital Tech To Capture Electronic Trial Data
Executive Summary
The European Medicines Agency has published a keenly awaited guidance document on how to use computerized systems in clinical trials while ensuring data integrity and patient rights.
You may also be interested in...
Principles-Based vs Prescriptive: How US & EU Compare In Their Approach To Decentralized Trials
In this regional comparison, regulatory experts at a US-based decentralized clinical trials (DCT) firm discuss their views on how the FDA’s draft DCT guideline compares with the pan-EU recommendation paper on this topic. This first segment of a two-part article dwells on the thinking behind why US and EU regulators tend to go down different paths.
EU Countries Focus On National Best Practices For Decentralized Trial Approvals & Inspections
The EU recommendation paper on decentralized clinical trials (DCTs) marked an important “first step” on the direction the European regulatory network wants to take with DCTs. Member states are now focused on reviewing and tracking DCTs to gain experience before considering the need for any updates to the recommendation paper.
Where Do The EU & The US Stand On Decentralized Clinical Trials?
Guidance on regulatory and data protection considerations for decentralized clinical trials varies widely between the EU and the US. Trial sponsors need to pay particular attention to issues such as missing data, informed consent and data collection, say lawyers from Sidley Austin.